当前位置: 首页 > 期刊 > 《医学信息》 > 2018年第7期
编号:13240490
缬沙坦对原发性高血压患者外周PBMC中IL—17表达的影响(1)
http://www.100md.com 2018年2月19日 《医学信息》 2018年第7期
     摘 要:目的 探討血管紧张素Ⅱ受体阻滞剂缬沙坦对高血压患者外周血单核细胞中IL-17表达的影响。方法 选取2016年9月~2017年10月在我院收治的原发性高血压患者98例,将所有患者按照随机数字表法分为缬沙坦组和硝苯地平组,各49例,缬沙坦组患者使用缬沙坦治疗,硝苯地平组患者使用硝苯地平缓释片治疗,另选取健康体检者20例为正常组。采集患者治疗前及治疗4周后静脉血,分离PBMC体外培养5 h后用RT-PCR法测定IL-17 mRNA表达水平;培养上清液采用ELISA法测定IL-17浓度。结果 治疗4周后缬沙坦组与硝苯地平组血压变化比较,差异无统计学意义(P>0.05);缬沙坦组治疗后PBMC中IL-17 mRNA表达及培养上清液中IL-17浓度分别为(0.29±0.09),(76.16±20.56)pg/ml,低于硝苯地平组的(0.50±0.15),(137.84±39.97)pg/ml,组间比较,差异有统计学意义(P<0.05)。结论 缬沙坦可显著降低高血压患者PBMC中IL-17的表达,有助于延缓疾病发展。

    关键词:缬沙坦;高血压;IL-17
, http://www.100md.com
    中图分类号:R544.1 文献标识码:A DOI:10.3969/j.issn.1006-1959.2018.07.021

    文章编号:1006-1959(2018)07-0065-04

    The Effect of Valsartan on the Expression of IL-17 in Peripheral PBMC of Patients with Essential Hypertension

    QIAO Jun1,2,GAO Xiang3,WANG Yu1,MEI Ren-biao1

    (1.Department of Medical Science and Research,Anhui University Of Science and Technology Medical College,Huainan 232001,Anhui,China;
, 百拇医药
    2.Department of Laboratory,Huainan Second People's Hospital,Huainan 232072,Anhui,China;

    3.Department of Internal Medicine,Huainan Second People's Hospital,Huainan 232072,Anhui,China)

    Abstract:Objective To investigate the effect of valsartan, an angiotensinⅡreceptor blocker,on the expression of IL-17 in peripheral blood monocytes of patients with hypertension.Methods 98 patients with essential hypertension admitted in our hospital from September 2016 to October 2017 were randomly divided into valsartan group and nifedipine group(49 cases each).Patients in valsartan group were treated with valsartan,nifedipine group was treated with nifedipine sustained release tablet,and 20 healthy cases were selected as normal group.Venous blood was collected before and after 4 weeks of treatment.The expression of IL-17 mRNA was measured by RT-PCR method after 5 h culture of PBMC in vitro,and the IL-17 concentration was measured by ELISA method in the supernatant of culture supernatant.Results After 4 weeks of treatment, there was no significant difference in blood pressure between valsartan group and nifedipine group,the difference was not statistically significant(P>0.05),the IL-17 mRNA expression in PBMC and the concentration of IL-17 in the culture supernatant of the valsartan group were(0.29±0.09),(76.16±20.56)pg/ml,respectively,lower than that of the nifedipine group(0.50±0.15),(137.84±39.97)pg/ml,the difference between the groups was statistically significant(P<0.05).Conclusion Valsartan can significantly reduce the expression of IL-17 in the PBMCs of hypertensive patients and help to delay the development of the disease., http://www.100md.com(乔君 高翔 王瑜 梅仁彪)
1 2 3下一页